FIGHT-207: Anonymized Genomic Alterations and Clinical Responses
Demographics (2)
- SEX - Biological sex (phv00537512.v1.p1)
- SUBJECT_ID - Subject ID (phv00537515.v1.p1)
Disease Events (1)
- FASTUCT2 - Harmonized solid tumor cancer type (phv00537518.v1.p1)
Other (19)
- ALTCOHORT - Genomic analysis assignment (phv00537516.v1.p1)
- ANALYTE_TYPE - Analyte type (phv00537528.v1.p1)
- BOR_INDEPENDENT_CONFIRMED - Best overall response - centrally confirmed (phv00537522.v1.p1)
- CENTRAL_BEST_PCHG_RANO - Centrally-assessed percent change baseline in sum of perpendicular diameters RANO (Response Assessment in Neuro-Oncology) (phv00537524.v1.p1)
- CENTRAL_BEST_PCHG_RECIST - Centrally-assessed percent change baseline in sum of diameters RECIST (phv00537523.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00537511.v1.p1)
- ENRLGENE - Enrollment FGFR gene (phv00537519.v1.p1)
- ENRLVAR - Enrollment variant, including point mutations and translocations to specified genes (phv00537521.v1.p1)
- ENRLVART - Enrollment variant type (phv00537520.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00537530.v1.p1)
- IS_TUMOR - Whether or not sample is from tumor (phv00537529.v1.p1)
- PFSC_AVAL - Centrally-assessed progression free survival (Days) (phv00537525.v1.p1)
- PFSC_CNSR - Centrally-assessed progression free survival - censored (phv00537526.v1.p1)
- SAMPLE_ID - Sample ID (phv00537527.v1.p1)
- SAMPLE_ID - Sample ID (phv00537514.v1.p1)
- SUBJECT_ID - Subject ID (phv00537510.v1.p1)
- SUBJECT_ID - Subject ID (phv00537513.v1.p1)
- TRT01A - Patient disposition cohort, as presented in the study description (phv00537517.v1.p1)
- VISIT - Visit at which sample was collected (phv00537531.v1.p1)